So far, only small molecules, peptides, modified chemokines and antibody fragments targeting ACKR3 have been reported, partly owing to the long-established importance of the CXCR4–CXCL12 axis in cancer, autoimmune and cardiovascular diseases (13, 70, 119, 120, 127–131). Here, CXCR4 is linked to cancer.